Pharma Commercial Mock
← All views
Competitive intelligence

CI feed

Conference abstracts + payer decisions interleaved chronologically — the CI team aims to publish a structured briefing within 48 hours of any high-relevance event landing here.

230 items in window · 103 high-relevance

type:allabstractspayer decisionsrelevance:allhighmediumlow
  1. Payerhigh (91%)cms lcdcoverage decision
    2025-06-01
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JFlives: 4,361,966effective: 2025-06-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  2. Payerhigh (88%)icervalue assessment draft
    2025-06-02
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 50,803,475effective: 2025-06-02
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: C+value_for_money: high
  3. Payermedium (61%)health plan commercialtier changed
    2025-06-02
    UnitedHealthcare moved ZENVARA from preferred to non-preferred tier.
    UnitedHealthcareUS-nationallives: 11,785,892effective: 2025-08-01
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  4. Payerhigh (73%)cms lcdcoverage decision
    2025-06-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J8lives: 8,889,156effective: 2025-06-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  5. Payerhigh (77%)pbm commercialtier changed
    2025-06-03
    Express Scripts moved ZENVARA from preferred to non-preferred tier.
    Express ScriptsUS-nationallives: 98,664,512effective: 2025-06-03
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 5
  6. Payermedium (66%)pbm commercialadded
    2025-06-03
    Express Scripts added ZENVARA to NSCLC formulary tier 3 with PA.
    Express ScriptsUS-nationallives: 82,839,689effective: 2025-06-10
    Decision targets ZENVARA's direct competitor in NSCLC.
  7. Payermedium (50%)va national formularyadded
    2025-06-03
    VA Pharmacy Benefits Management added ZENVARA to NSCLC formulary tier 3 with PA.
    VA Pharmacy Benefits ManagementUS-nationallives: 8,888,996effective: 2025-06-03
    Decision affects adjacent indication; potential read-through to ZENVARA.
  8. Payermedium (46%)hta intlvalue assessment final
    2025-06-04
    HAS (France) published final value assessment for ZENVARA in NSCLC.
    HAS (France)UKlives: 17,329,018effective: 2025-06-04
    Class-wide implications relevant to all assets with this mechanism.
  9. Payerhigh (89%)health plan commercialrestriction added
    2025-06-04
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 12,182,866effective: 2025-07-20
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  10. Payerhigh (70%)state medicaid pdlremoved
    2025-06-04
    Florida AHCA removed ZENVARA from formulary effective 2025-07-28.
    Florida AHCAUS-state:MIlives: 7,061,543effective: 2025-07-28
    Decision targets ZENVARA's direct competitor in NSCLC.
  11. Payerhigh (92%)health plan commercialrestriction added
    2025-06-05
    UnitedHealthcare added prior-authorization requirement to ZENVARA.
    UnitedHealthcareUS-nationallives: 8,642,708effective: 2025-06-05
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA,ST
  12. Payerhigh (72%)state medicaid pdladded
    2025-06-05
    Florida AHCA added ZENVARA to NSCLC formulary tier 3 with PA.
    Florida AHCAUS-state:OHlives: 11,627,914effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  13. Payerhigh (91%)health plan commercialrestriction added
    2025-06-05
    UnitedHealthcare added prior-authorization requirement to ZENVARA.
    UnitedHealthcareUS-nationallives: 11,134,149effective: 2025-07-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,QL
  14. Payerhigh (87%)pbm commercialstep therapy imposed
    2025-06-06
    Express Scripts now requires step therapy through alternative before ZENVARA.
    Express ScriptsUS-nationallives: 82,929,630effective: 2025-06-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  15. Payerlow (36%)state medicaid pdladded
    2025-06-06
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:PAlives: 14,726,433effective: 2025-07-22
    Decision affects adjacent indication; potential read-through to ZENVARA.
  16. Payerhigh (71%)pbm medicare pdpremoved
    2025-06-09
    CVS Caremark SilverScript removed ZENVARA from formulary effective 2025-06-20.
    CVS Caremark SilverScriptUS-nationallives: 10,197,183effective: 2025-06-20
    Decision targets ZENVARA's direct competitor in NSCLC.
  17. Payerlow (23%)state medicaid pdlremoved
    2025-06-09
    California DHCS removed ZENVARA from formulary effective 2025-06-10.
    California DHCSUS-state:GAlives: 14,597,840effective: 2025-06-10
    Decision concerns ZENVARA's reference product.
  18. Payerhigh (81%)state medicaid pdladded
    2025-06-10
    Ohio DODD added ZENVARA to NSCLC formulary tier 3 with PA.
    Ohio DODDUS-state:MIlives: 13,722,489effective: 2025-07-15
    Decision targets ZENVARA's direct competitor in NSCLC.
  19. Payerhigh (79%)pbm commercialstep therapy imposed
    2025-06-10
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 70,948,713effective: 2025-06-29
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  20. Payerhigh (87%)hta intlvalue assessment final
    2025-06-11
    CADTH (Canada) published final value assessment for ZENVARA in NSCLC.
    CADTH (Canada)UKlives: 47,166,600effective: 2025-06-11
    Decision targets ZENVARA's direct competitor in NSCLC.
  21. Payerhigh (73%)pbm commercialrestriction added
    2025-06-12
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 73,132,320effective: 2025-07-10
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL,LA
  22. Payerhigh (72%)state medicaid pdladded
    2025-06-12
    California DHCS added ZENVARA to NSCLC formulary tier 3 with PA.
    California DHCSUS-state:FLlives: 5,773,802effective: 2025-07-20
    Decision targets ZENVARA's direct competitor in NSCLC.
  23. Payerhigh (88%)hta intlcoverage decision
    2025-06-13
    CADTH (Canada) issued coverage decision for ZENVARA in NSCLC.
    CADTH (Canada)UKlives: 41,898,018effective: 2025-06-13
    Decision targets ZENVARA's direct competitor in NSCLC.
  24. Payermedium (66%)pbm commercialadded
    2025-06-13
    OptumRx added ZENVARA to NSCLC formulary tier 3 with PA.
    OptumRxUS-nationallives: 75,035,003effective: 2025-07-10
    Decision targets ZENVARA's direct competitor in NSCLC.
  25. Payerlow (38%)pbm medicare pdpadded
    2025-06-13
    Express Scripts Medicare added ZENVARA to NSCLC formulary tier 3 with PA.
    Express Scripts MedicareUS-nationallives: 8,272,569effective: 2025-06-30
    Decision affects adjacent indication; potential read-through to ZENVARA.
  26. Payerhigh (95%)cms lcdcoverage decision
    2025-06-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 3,580,272effective: 2025-06-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  27. Payermedium (61%)va national formularyadded
    2025-06-15
    VA Pharmacy Benefits Management added ZENVARA to NSCLC formulary tier 3 with PA.
    VA Pharmacy Benefits ManagementUS-nationallives: 9,301,763effective: 2025-08-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  28. Payermedium (64%)health plan commercialrestriction removed
    2025-06-15
    Kaiser Permanente removed step-therapy requirement on ZENVARA.
    Kaiser PermanenteUS-nationallives: 20,415,265effective: 2025-06-15
    Decision targets ZENVARA's direct competitor in NSCLC.
  29. Payerlow (39%)pbm medicare pdprestriction added
    2025-06-15
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 5,391,705effective: 2025-07-28
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: QL
  30. Payerhigh (89%)icervalue assessment draft
    2025-06-16
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 55,776,217effective: 2025-06-16
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: Avalue_for_money: intermediateprice_benchmark_usd: 98748
  31. Payerhigh (74%)state medicaid pdladded
    2025-06-16
    Pennsylvania DHS added ZENVARA to NSCLC formulary tier 3 with PA.
    Pennsylvania DHSUS-state:MIlives: 10,609,773effective: 2025-06-18
    Decision targets ZENVARA's direct competitor in NSCLC.
  32. Payerhigh (79%)hta intlvalue assessment final
    2025-06-16
    HAS (France) published final value assessment for ZENVARA in NSCLC.
    HAS (France)EU-DElives: 6,716,500effective: 2025-06-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  33. Payermedium (63%)state medicaid pdladded
    2025-06-17
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:MIlives: 10,468,409effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  34. Payermedium (68%)state medicaid pdlpdl preferred status changed
    2025-06-17
    New York DOH updated PDL preferred status for ZENVARA.
    New York DOHUS-state:CAlives: 11,869,624effective: 2025-06-17
    Decision targets ZENVARA's direct competitor in NSCLC.
  35. Payerhigh (77%)state medicaid pdladded
    2025-06-17
    Pennsylvania DHS added ZENVARA to NSCLC formulary tier 3 with PA.
    Pennsylvania DHSUS-state:MIlives: 7,897,252effective: 2025-08-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  36. Payerlow (20%)dod tricareremoved
    2025-06-17
    DoD TRICARE removed ZENVARA from formulary effective 2025-07-25.
    DoD TRICAREUS-nationallives: 9,075,802effective: 2025-07-25
    Decision affects adjacent indication; potential read-through to ZENVARA.
  37. Payerlow (29%)hta intlvalue assessment final
    2025-06-19
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)EU-DElives: 39,012,354effective: 2025-06-19
    Class-wide implications relevant to all assets with this mechanism.
  38. Payerlow (20%)hospital pt committeeadded
    2025-06-20
    HCA Healthcare added ZENVARA to NSCLC formulary tier 3 with PA.
    HCA HealthcareUS-nationallives: 457,769effective: 2025-08-12
    Class-wide implications relevant to all assets with this mechanism.
  39. Payermedium (54%)hospital pt committeeadded
    2025-06-21
    Ascension added ZENVARA to NSCLC formulary tier 3 with PA.
    AscensionUS-nationallives: 357,466effective: 2025-07-23
    Decision concerns ZENVARA's reference product.
  40. Payerlow (21%)pbm medicare pdptier changed
    2025-06-21
    Humana Pharmacy Solutions moved ZENVARA from preferred to non-preferred tier.
    Humana Pharmacy SolutionsUS-nationallives: 7,345,172effective: 2025-07-16
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 4
  41. Payermedium (45%)state medicaid pdlremoved
    2025-06-22
    Texas HHSC removed ZENVARA from formulary effective 2025-07-30.
    Texas HHSCUS-state:MIlives: 2,389,692effective: 2025-07-30
    Decision concerns ZENVARA's reference product.
  42. Payerhigh (78%)pbm medicare pdptier changed
    2025-06-23
    Humana Pharmacy Solutions moved ZENVARA from preferred to non-preferred tier.
    Humana Pharmacy SolutionsUS-nationallives: 5,763,465effective: 2025-06-28
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  43. Payermedium (50%)health plan commercialrestriction added
    2025-06-23
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 19,401,818effective: 2025-06-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA
  44. Payerhigh (94%)cms ncdcoverage decision
    2025-06-23
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,588,984effective: 2025-06-23
    Decision targets ZENVARA's direct competitor in NSCLC.
  45. Payerhigh (93%)cms ncdcoverage decision
    2025-06-24
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,220,974effective: 2025-06-24
    Decision targets ZENVARA's direct competitor in NSCLC.
  46. Payermedium (62%)pbm commercialrestriction added
    2025-06-25
    OptumRx added prior-authorization requirement to ZENVARA.
    OptumRxUS-nationallives: 63,888,214effective: 2025-06-25
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  47. Payerhigh (92%)pbm commercialrestriction added
    2025-06-27
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 85,978,174effective: 2025-06-30
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  48. Payerhigh (76%)state medicaid pdladded
    2025-06-27
    Florida AHCA added ZENVARA to NSCLC formulary tier 3 with PA.
    Florida AHCAUS-state:FLlives: 12,685,899effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  49. Payermedium (49%)va national formularyrestriction added
    2025-06-28
    VA Pharmacy Benefits Management added prior-authorization requirement to ZENVARA.
    VA Pharmacy Benefits ManagementUS-nationallives: 8,621,008effective: 2025-08-23
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA
  50. Payermedium (66%)pbm medicare pdpadded
    2025-06-28
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 11,381,927effective: 2025-08-10
    Decision targets ZENVARA's direct competitor in NSCLC.
  51. Payermedium (50%)cms ncdcoverage decision
    2025-06-29
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,239,095effective: 2025-06-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
  52. Payerlow (20%)pbm commercialadded
    2025-06-30
    Express Scripts added ZENVARA to NSCLC formulary tier 3 with PA.
    Express ScriptsUS-nationallives: 85,843,785effective: 2025-08-29
    Class-wide implications relevant to all assets with this mechanism.
  53. Payerhigh (75%)pbm commercialtier changed
    2025-06-30
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 85,127,933effective: 2025-07-07
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 4
  54. Payerlow (21%)cms lcdcoverage decision
    2025-07-01
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J15lives: 8,924,098effective: 2025-07-01
    Decision concerns ZENVARA's reference product.
  55. Payerhigh (94%)health plan commercialrestriction removed
    2025-07-01
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 11,057,130effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  56. Payermedium (60%)pbm medicare pdprestriction added
    2025-07-01
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 4,960,790effective: 2025-08-16
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  57. Payermedium (52%)state medicaid pdlremoved
    2025-07-01
    Florida AHCA removed ZENVARA from formulary effective 2025-08-26.
    Florida AHCAUS-state:GAlives: 2,782,010effective: 2025-08-26
    Class-wide implications relevant to all assets with this mechanism.
  58. Payerlow (20%)pbm commercialstep therapy imposed
    2025-07-02
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 86,120,052effective: 2025-08-18
    Decision concerns ZENVARA's reference product.
    restrictions: QL,PA
  59. Payerlow (29%)state medicaid pdlremoved
    2025-07-02
    Texas HHSC removed ZENVARA from formulary effective 2025-08-24.
    Texas HHSCUS-state:MIlives: 6,741,526effective: 2025-08-24
    Class-wide implications relevant to all assets with this mechanism.
  60. Payermedium (55%)state medicaid pdladded
    2025-07-02
    Pennsylvania DHS added ZENVARA to NSCLC formulary tier 3 with PA.
    Pennsylvania DHSUS-state:TXlives: 2,308,782effective: 2025-07-03
    Decision concerns ZENVARA's reference product.
  61. Payerhigh (73%)hta intlvalue assessment final
    2025-07-02
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)EU-FRlives: 51,472,238effective: 2025-07-02
    Decision targets ZENVARA's direct competitor in NSCLC.
  62. Payerhigh (73%)health plan commercialrestriction added
    2025-07-03
    BCBS Federal Employee Program added prior-authorization requirement to ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 6,850,548effective: 2025-07-07
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  63. Payermedium (53%)cms ncdcoverage decision
    2025-07-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 61,878,624effective: 2025-07-03
    Decision affects adjacent indication; potential read-through to ZENVARA.
  64. Payerhigh (83%)icervalue assessment final
    2025-07-04
    ICER published final value assessment for ZENVARA in NSCLC.
    ICERUS-nationallives: 65,882,802effective: 2025-07-04
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: C+value_for_money: highprice_benchmark_usd: 155336
  65. Payermedium (66%)cms lcdcoverage decision
    2025-07-04
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J15lives: 10,103,223effective: 2025-07-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  66. Payerlow (34%)cms lcdcoverage decision
    2025-07-06
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 3,910,041effective: 2025-07-06
    Class-wide implications relevant to all assets with this mechanism.
  67. Payerhigh (70%)hospital pt committeerestriction added
    2025-07-06
    Ascension added prior-authorization requirement to ZENVARA.
    AscensionUS-nationallives: 636,467effective: 2025-07-21
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,PA
  68. Payerhigh (72%)pbm medicare pdpadded
    2025-07-07
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 8,421,949effective: 2025-08-17
    Decision targets ZENVARA's direct competitor in NSCLC.
  69. Payermedium (51%)pbm medicare pdpadded
    2025-07-07
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 11,904,986effective: 2025-07-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
  70. Payerhigh (70%)health plan commercialtier changed
    2025-07-07
    BCBS Federal Employee Program moved ZENVARA from preferred to non-preferred tier.
    BCBS Federal Employee ProgramUS-nationallives: 21,664,802effective: 2025-08-13
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  71. Payerhigh (86%)pbm medicare pdpadded
    2025-07-07
    CVS Caremark SilverScript added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS Caremark SilverScriptUS-nationallives: 7,969,893effective: 2025-07-19
    Decision targets ZENVARA's direct competitor in NSCLC.
  72. Payermedium (53%)state medicaid pdlpdl preferred status changed
    2025-07-08
    California DHCS updated PDL preferred status for ZENVARA.
    California DHCSUS-state:FLlives: 4,286,117effective: 2025-07-08
    Decision affects adjacent indication; potential read-through to ZENVARA.
  73. Payerhigh (91%)health plan commercialtier changed
    2025-07-08
    Aetna moved ZENVARA from preferred to non-preferred tier.
    AetnaUS-nationallives: 24,735,149effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 3
  74. Payerhigh (70%)hta intlcoverage decision
    2025-07-08
    NICE (UK) issued coverage decision for ZENVARA in NSCLC.
    NICE (UK)EU-FRlives: 44,125,340effective: 2025-07-08
    Decision targets ZENVARA's direct competitor in NSCLC.
  75. Payerlow (34%)state medicaid pdlpdl preferred status changed
    2025-07-11
    Florida AHCA updated PDL preferred status for ZENVARA.
    Florida AHCAUS-state:NYlives: 11,504,070effective: 2025-07-11
    Class-wide implications relevant to all assets with this mechanism.
  76. Payermedium (47%)va national formularyadded
    2025-07-13
    VA Pharmacy Benefits Management added ZENVARA to NSCLC formulary tier 3 with PA.
    VA Pharmacy Benefits ManagementUS-nationallives: 9,479,567effective: 2025-09-08
    Decision affects adjacent indication; potential read-through to ZENVARA.
  77. Payermedium (51%)pbm commercialadded
    2025-07-13
    OptumRx added ZENVARA to NSCLC formulary tier 3 with PA.
    OptumRxUS-nationallives: 75,891,098effective: 2025-07-28
    Class-wide implications relevant to all assets with this mechanism.
  78. Payerlow (29%)pbm medicare pdpremoved
    2025-07-15
    CVS Caremark SilverScript removed ZENVARA from formulary effective 2025-07-15.
    CVS Caremark SilverScriptUS-nationallives: 8,152,209effective: 2025-07-15
    Decision affects adjacent indication; potential read-through to ZENVARA.
  79. Payerhigh (82%)pbm commercialrestriction added
    2025-07-16
    Express Scripts added prior-authorization requirement to ZENVARA.
    Express ScriptsUS-nationallives: 97,353,887effective: 2025-09-01
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,LA
  80. Payermedium (43%)hospital pt committeerestriction added
    2025-07-17
    Ascension added prior-authorization requirement to ZENVARA.
    AscensionUS-nationallives: 928,899effective: 2025-08-20
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: ST
  81. Payerlow (32%)state medicaid pdlpdl preferred status changed
    2025-07-17
    California DHCS updated PDL preferred status for ZENVARA.
    California DHCSUS-state:CAlives: 12,118,580effective: 2025-07-17
    Decision affects adjacent indication; potential read-through to ZENVARA.
  82. Payerlow (35%)health plan commercialtier changed
    2025-07-17
    Aetna moved ZENVARA from preferred to non-preferred tier.
    AetnaUS-nationallives: 14,166,090effective: 2025-09-12
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 3tier_after: 3
  83. Payerhigh (89%)pbm medicare pdprestriction added
    2025-07-17
    Express Scripts Medicare added prior-authorization requirement to ZENVARA.
    Express Scripts MedicareUS-nationallives: 10,469,373effective: 2025-08-27
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,PA
  84. Payerlow (32%)pbm commercialexcluded
    2025-07-18
    Express Scripts excluded ZENVARA from 2026 formulary effective 2025-08-02.
    Express ScriptsUS-nationallives: 78,161,365effective: 2025-08-02
    Decision affects adjacent indication; potential read-through to ZENVARA.
  85. Payerlow (26%)pbm commercialrestriction added
    2025-07-18
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 88,088,431effective: 2025-08-22
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: ST
  86. Payermedium (40%)state medicaid pdladded
    2025-07-19
    Florida AHCA added ZENVARA to NSCLC formulary tier 3 with PA.
    Florida AHCAUS-state:OHlives: 5,290,386effective: 2025-08-04
    Decision concerns ZENVARA's reference product.
  87. Payerhigh (75%)health plan commercialrestriction added
    2025-07-20
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 9,210,226effective: 2025-09-13
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL,ST
  88. Payerhigh (90%)hospital pt committeeadded
    2025-07-20
    Kaiser Hospitals added ZENVARA to NSCLC formulary tier 3 with PA.
    Kaiser HospitalsUS-nationallives: 1,371,864effective: 2025-09-12
    Decision targets ZENVARA's direct competitor in NSCLC.
  89. Payerlow (29%)cms lcdcoverage decision
    2025-07-21
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 11,993,039effective: 2025-07-21
    Decision affects adjacent indication; potential read-through to ZENVARA.
  90. Payerlow (26%)cms lcdcoverage decision
    2025-07-21
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JNlives: 8,175,588effective: 2025-07-21
    Decision affects adjacent indication; potential read-through to ZENVARA.
  91. Payerhigh (75%)state medicaid pdladded
    2025-07-21
    Ohio DODD added ZENVARA to NSCLC formulary tier 3 with PA.
    Ohio DODDUS-state:ILlives: 12,779,672effective: 2025-09-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  92. Payerhigh (95%)pbm medicare pdpremoved
    2025-07-22
    Humana Pharmacy Solutions removed ZENVARA from formulary effective 2025-09-16.
    Humana Pharmacy SolutionsUS-nationallives: 5,600,467effective: 2025-09-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  93. Payerhigh (93%)cms lcdcoverage decision
    2025-07-23
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JFlives: 11,182,172effective: 2025-07-23
    Decision targets ZENVARA's direct competitor in NSCLC.
  94. Payermedium (63%)pbm commercialstep therapy imposed
    2025-07-23
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 84,078,547effective: 2025-08-21
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,PA
  95. Payermedium (52%)state medicaid pdlpdl preferred status changed
    2025-07-25
    Texas HHSC updated PDL preferred status for ZENVARA.
    Texas HHSCUS-state:ILlives: 7,751,414effective: 2025-07-25
    Class-wide implications relevant to all assets with this mechanism.
  96. Payerhigh (79%)cms lcdcoverage decision
    2025-07-25
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J5lives: 5,566,890effective: 2025-07-25
    Decision targets ZENVARA's direct competitor in NSCLC.
  97. Payermedium (42%)cms lcdcoverage decision
    2025-07-26
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JNlives: 5,601,401effective: 2025-07-26
    Class-wide implications relevant to all assets with this mechanism.
  98. Payermedium (67%)cms lcdcoverage decision
    2025-07-26
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JLlives: 7,606,429effective: 2025-07-26
    Decision targets ZENVARA's direct competitor in NSCLC.
  99. Payermedium (66%)hospital pt committeerestriction added
    2025-07-26
    CommonSpirit Health added prior-authorization requirement to ZENVARA.
    CommonSpirit HealthUS-nationallives: 1,601,801effective: 2025-09-03
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA,LA
  100. Payerhigh (93%)cms lcdcoverage decision
    2025-07-27
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J6lives: 5,979,461effective: 2025-07-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  101. Payermedium (69%)hospital pt committeeremoved
    2025-07-29
    Ascension removed ZENVARA from formulary effective 2025-09-16.
    AscensionUS-nationallives: 859,723effective: 2025-09-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  102. Payerlow (23%)health plan commercialtier changed
    2025-07-29
    Cigna moved ZENVARA from preferred to non-preferred tier.
    CignaUS-nationallives: 25,295,976effective: 2025-09-21
    Decision concerns ZENVARA's reference product.
    tier_before: 3tier_after: 4
  103. Payerlow (33%)pbm commercialadded
    2025-07-31
    Express Scripts added ZENVARA to NSCLC formulary tier 3 with PA.
    Express ScriptsUS-nationallives: 65,082,531effective: 2025-08-24
    Class-wide implications relevant to all assets with this mechanism.
  104. Payermedium (64%)pbm commercialexcluded
    2025-07-31
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-09-04.
    OptumRxUS-nationallives: 103,851,148effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  105. Payerhigh (78%)pbm commercialtier changed
    2025-08-03
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 90,521,897effective: 2025-09-12
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 5
  106. Payerhigh (79%)cms lcdcoverage decision
    2025-08-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JFlives: 5,230,248effective: 2025-08-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  107. Payermedium (61%)cms ncdcoverage decision
    2025-08-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 62,634,101effective: 2025-08-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  108. Payermedium (62%)state medicaid pdlremoved
    2025-08-03
    Pennsylvania DHS removed ZENVARA from formulary effective 2025-08-27.
    Pennsylvania DHSUS-state:NYlives: 6,077,599effective: 2025-08-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  109. Payerlow (29%)icervalue assessment draft
    2025-08-04
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 56,921,292effective: 2025-08-04
    Decision affects adjacent indication; potential read-through to ZENVARA.
    rating: C-value_for_money: intermediateprice_benchmark_usd: 28106
  110. Payermedium (55%)health plan commercialrestriction added
    2025-08-05
    BCBS Federal Employee Program added prior-authorization requirement to ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 11,062,358effective: 2025-09-16
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: PA
  111. Payermedium (69%)hta intlvalue assessment final
    2025-08-05
    G-BA (Germany) published final value assessment for ZENVARA in NSCLC.
    G-BA (Germany)EU-DElives: 12,945,419effective: 2025-08-05
    Decision targets ZENVARA's direct competitor in NSCLC.
  112. Payermedium (60%)pbm commercialtier changed
    2025-08-06
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 61,556,077effective: 2025-09-22
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 3
  113. Payermedium (69%)pbm medicare pdpadded
    2025-08-06
    Express Scripts Medicare added ZENVARA to NSCLC formulary tier 3 with PA.
    Express Scripts MedicareUS-nationallives: 7,948,955effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  114. Payermedium (65%)dod tricareremoved
    2025-08-07
    DoD TRICARE removed ZENVARA from formulary effective 2025-09-28.
    DoD TRICAREUS-nationallives: 9,874,504effective: 2025-09-28
    Decision targets ZENVARA's direct competitor in NSCLC.
  115. Payerlow (31%)cms lcdcoverage decision
    2025-08-08
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J5lives: 3,931,525effective: 2025-08-08
    Decision affects adjacent indication; potential read-through to ZENVARA.
  116. Payerhigh (74%)health plan commercialrestriction removed
    2025-08-08
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 6,988,605effective: 2025-08-08
    Decision targets ZENVARA's direct competitor in NSCLC.
  117. Payerhigh (95%)pbm commercialrestriction added
    2025-08-08
    Express Scripts added prior-authorization requirement to ZENVARA.
    Express ScriptsUS-nationallives: 85,126,875effective: 2025-09-27
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  118. Payerlow (28%)pbm commercialadded
    2025-08-09
    CVS Caremark added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS CaremarkUS-nationallives: 80,513,617effective: 2025-09-02
    Decision concerns ZENVARA's reference product.
  119. Payerhigh (74%)pbm medicare pdptier changed
    2025-08-10
    OptumRx Medicare moved ZENVARA from preferred to non-preferred tier.
    OptumRx MedicareUS-nationallives: 3,635,948effective: 2025-09-10
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 3
  120. Payerhigh (81%)pbm commercialrestriction added
    2025-08-10
    Express Scripts added prior-authorization requirement to ZENVARA.
    Express ScriptsUS-nationallives: 99,063,045effective: 2025-08-29
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA
  121. Payerhigh (85%)health plan commercialrestriction added
    2025-08-10
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 18,594,702effective: 2025-09-06
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,PA
  122. Payerlow (30%)pbm medicare pdpremoved
    2025-08-11
    Humana Pharmacy Solutions removed ZENVARA from formulary effective 2025-09-27.
    Humana Pharmacy SolutionsUS-nationallives: 11,910,809effective: 2025-09-27
    Decision affects adjacent indication; potential read-through to ZENVARA.
  123. Payerhigh (82%)state medicaid pdlpdl preferred status changed
    2025-08-11
    Florida AHCA updated PDL preferred status for ZENVARA.
    Florida AHCAUS-state:ILlives: 5,134,104effective: 2025-08-11
    Decision targets ZENVARA's direct competitor in NSCLC.
  124. Payerlow (28%)health plan commercialrestriction added
    2025-08-11
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 20,452,530effective: 2025-09-30
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: PA
  125. Payermedium (45%)health plan commercialrestriction removed
    2025-08-12
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 22,614,523effective: 2025-08-12
    Decision affects adjacent indication; potential read-through to ZENVARA.
  126. Payermedium (47%)pbm commercialstep therapy imposed
    2025-08-13
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 96,094,770effective: 2025-09-13
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA,ST
  127. Payermedium (51%)pbm commercialtier changed
    2025-08-13
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 70,846,268effective: 2025-08-13
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 5
  128. Payerhigh (89%)cms lcdcoverage decision
    2025-08-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 9,797,625effective: 2025-08-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  129. Payermedium (48%)state medicaid pdlremoved
    2025-08-14
    Texas HHSC removed ZENVARA from formulary effective 2025-09-15.
    Texas HHSCUS-state:TXlives: 12,088,622effective: 2025-09-15
    Decision affects adjacent indication; potential read-through to ZENVARA.
  130. Payerhigh (78%)pbm medicare pdpremoved
    2025-08-15
    OptumRx Medicare removed ZENVARA from formulary effective 2025-10-06.
    OptumRx MedicareUS-nationallives: 3,364,598effective: 2025-10-06
    Decision targets ZENVARA's direct competitor in NSCLC.
  131. Payermedium (42%)hospital pt committeeremoved
    2025-08-15
    CommonSpirit Health removed ZENVARA from formulary effective 2025-08-23.
    CommonSpirit HealthUS-nationallives: 256,998effective: 2025-08-23
    Decision affects adjacent indication; potential read-through to ZENVARA.
  132. Payerhigh (73%)pbm medicare pdptier changed
    2025-08-15
    Humana Pharmacy Solutions moved ZENVARA from preferred to non-preferred tier.
    Humana Pharmacy SolutionsUS-nationallives: 10,563,302effective: 2025-09-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  133. Payerlow (25%)pbm commercialstep therapy imposed
    2025-08-15
    Express Scripts now requires step therapy through alternative before ZENVARA.
    Express ScriptsUS-nationallives: 78,388,248effective: 2025-08-31
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: PA
  134. Payermedium (46%)health plan commercialrestriction removed
    2025-08-15
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 14,431,683effective: 2025-08-15
    Class-wide implications relevant to all assets with this mechanism.
  135. Payerhigh (72%)dod tricareremoved
    2025-08-16
    DoD TRICARE removed ZENVARA from formulary effective 2025-09-02.
    DoD TRICAREUS-nationallives: 9,785,143effective: 2025-09-02
    Decision targets ZENVARA's direct competitor in NSCLC.
  136. Payerhigh (71%)hta intlvalue assessment final
    2025-08-16
    CADTH (Canada) published final value assessment for ZENVARA in NSCLC.
    CADTH (Canada)UKlives: 39,347,094effective: 2025-08-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  137. Payerhigh (86%)icerprice benchmark
    2025-08-16
    ICER updated value-based price benchmark for ZENVARA.
    ICERUS-nationallives: 75,918,902effective: 2025-08-16
    Decision targets ZENVARA's direct competitor in NSCLC.
    price_benchmark_usd: 66661value_for_money: low
  138. Payerhigh (72%)cms lcdcoverage decision
    2025-08-18
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JLlives: 8,163,922effective: 2025-08-18
    Decision targets ZENVARA's direct competitor in NSCLC.
  139. Payerhigh (72%)pbm commercialadded
    2025-08-18
    CVS Caremark added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS CaremarkUS-nationallives: 77,995,825effective: 2025-10-06
    Decision targets ZENVARA's direct competitor in NSCLC.
  140. Payerlow (23%)cms lcdcoverage decision
    2025-08-18
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J8lives: 3,450,700effective: 2025-08-18
    Decision affects adjacent indication; potential read-through to ZENVARA.
  141. Payermedium (61%)icervalue assessment draft
    2025-08-19
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 53,976,744effective: 2025-08-19
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: C-value_for_money: lowprice_benchmark_usd: 146627
  142. Payerhigh (80%)pbm commercialtier changed
    2025-08-21
    OptumRx moved ZENVARA from preferred to non-preferred tier.
    OptumRxUS-nationallives: 89,496,886effective: 2025-09-13
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  143. Payermedium (44%)icerprice benchmark
    2025-08-22
    ICER updated value-based price benchmark for ZENVARA.
    ICERUS-nationallives: 54,075,372effective: 2025-08-22
    Decision affects adjacent indication; potential read-through to ZENVARA.
    price_benchmark_usd: 135092value_for_money: intermediate
  144. Payerhigh (91%)state medicaid pdladded
    2025-08-25
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:MIlives: 8,291,671effective: 2025-08-30
    Decision targets ZENVARA's direct competitor in NSCLC.
  145. Payerhigh (87%)pbm commercialstep therapy imposed
    2025-08-27
    Express Scripts now requires step therapy through alternative before ZENVARA.
    Express ScriptsUS-nationallives: 78,263,110effective: 2025-09-23
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,QL
  146. Payermedium (67%)hta intlvalue assessment final
    2025-08-27
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)CAlives: 38,000,992effective: 2025-08-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  147. Payerhigh (71%)hospital pt committeeadded
    2025-08-28
    HCA Healthcare added ZENVARA to NSCLC formulary tier 3 with PA.
    HCA HealthcareUS-nationallives: 671,490effective: 2025-10-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  148. Payerlow (33%)cms lcdcoverage decision
    2025-08-29
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JNlives: 11,579,134effective: 2025-08-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
  149. Payerhigh (72%)state medicaid pdladded
    2025-08-30
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:FLlives: 8,125,512effective: 2025-09-12
    Decision targets ZENVARA's direct competitor in NSCLC.
  150. Payerlow (36%)hospital pt committeeadded
    2025-08-31
    Ascension added ZENVARA to NSCLC formulary tier 3 with PA.
    AscensionUS-nationallives: 923,211effective: 2025-10-08
    Class-wide implications relevant to all assets with this mechanism.
  151. Payerlow (29%)health plan commercialrestriction removed
    2025-08-31
    BCBS Federal Employee Program removed step-therapy requirement on ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 7,374,306effective: 2025-08-31
    Decision affects adjacent indication; potential read-through to ZENVARA.
  152. Payerlow (21%)hta intlcoverage decision
    2025-09-02
    G-BA (Germany) issued coverage decision for ZENVARA in NSCLC.
    G-BA (Germany)EU-DElives: 36,279,145effective: 2025-09-02
    Decision affects adjacent indication; potential read-through to ZENVARA.
  153. Payerhigh (92%)icervalue assessment final
    2025-09-02
    ICER published final value assessment for ZENVARA in NSCLC.
    ICERUS-nationallives: 52,097,687effective: 2025-09-02
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: Avalue_for_money: intermediate
  154. Payerhigh (73%)hta intlcoverage decision
    2025-09-04
    HAS (France) issued coverage decision for ZENVARA in NSCLC.
    HAS (France)EU-DElives: 53,487,154effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  155. Payermedium (46%)health plan commercialtier changed
    2025-09-04
    BCBS Federal Employee Program moved ZENVARA from preferred to non-preferred tier.
    BCBS Federal Employee ProgramUS-nationallives: 19,419,551effective: 2025-09-12
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 4
  156. Payerhigh (75%)cms ncdcoverage decision
    2025-09-05
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 63,826,503effective: 2025-09-05
    Decision targets ZENVARA's direct competitor in NSCLC.
  157. Payerhigh (71%)va national formularyremoved
    2025-09-06
    VA Pharmacy Benefits Management removed ZENVARA from formulary effective 2025-10-11.
    VA Pharmacy Benefits ManagementUS-nationallives: 8,895,017effective: 2025-10-11
    Decision targets ZENVARA's direct competitor in NSCLC.
  158. Payerlow (31%)pbm medicare pdpremoved
    2025-09-06
    Express Scripts Medicare removed ZENVARA from formulary effective 2025-09-26.
    Express Scripts MedicareUS-nationallives: 5,985,157effective: 2025-09-26
    Class-wide implications relevant to all assets with this mechanism.
  159. Payermedium (52%)cms lcdcoverage decision
    2025-09-08
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J5lives: 7,979,811effective: 2025-09-08
    Class-wide implications relevant to all assets with this mechanism.
  160. Payermedium (67%)cms lcdcoverage decision
    2025-09-09
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J8lives: 6,613,739effective: 2025-09-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  161. Payerhigh (74%)hospital pt committeeremoved
    2025-09-11
    HCA Healthcare removed ZENVARA from formulary effective 2025-09-27.
    HCA HealthcareUS-nationallives: 813,935effective: 2025-09-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  162. Payerlow (22%)health plan commercialrestriction removed
    2025-09-12
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 15,286,678effective: 2025-09-12
    Class-wide implications relevant to all assets with this mechanism.
  163. Payerhigh (75%)hospital pt committeeadded
    2025-09-12
    HCA Healthcare added ZENVARA to NSCLC formulary tier 3 with PA.
    HCA HealthcareUS-nationallives: 346,505effective: 2025-09-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  164. Payermedium (64%)health plan commercialrestriction removed
    2025-09-13
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 20,297,150effective: 2025-09-13
    Decision targets ZENVARA's direct competitor in NSCLC.
  165. Payermedium (52%)cms ncdcoverage decision
    2025-09-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 63,864,823effective: 2025-09-14
    Decision concerns ZENVARA's reference product.
  166. Payermedium (67%)cms lcdcoverage decision
    2025-09-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JMlives: 8,155,597effective: 2025-09-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  167. Payerlow (37%)pbm medicare pdpremoved
    2025-09-14
    Humana Pharmacy Solutions removed ZENVARA from formulary effective 2025-10-09.
    Humana Pharmacy SolutionsUS-nationallives: 10,370,520effective: 2025-10-09
    Decision concerns ZENVARA's reference product.
  168. Payerhigh (93%)health plan commercialrestriction removed
    2025-09-14
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 9,077,183effective: 2025-09-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  169. Payermedium (69%)state medicaid pdlremoved
    2025-09-17
    New York DOH removed ZENVARA from formulary effective 2025-10-27.
    New York DOHUS-state:PAlives: 9,199,503effective: 2025-10-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  170. Payermedium (65%)va national formularyrestriction added
    2025-09-17
    VA Pharmacy Benefits Management added prior-authorization requirement to ZENVARA.
    VA Pharmacy Benefits ManagementUS-nationallives: 9,246,996effective: 2025-09-28
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  171. Payerhigh (84%)hospital pt committeerestriction added
    2025-09-18
    CommonSpirit Health added prior-authorization requirement to ZENVARA.
    CommonSpirit HealthUS-nationallives: 726,705effective: 2025-11-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  172. Payerhigh (93%)state medicaid pdladded
    2025-09-18
    New York DOH added ZENVARA to NSCLC formulary tier 3 with PA.
    New York DOHUS-state:FLlives: 14,073,489effective: 2025-10-30
    Decision targets ZENVARA's direct competitor in NSCLC.
  173. Payermedium (60%)health plan commercialrestriction removed
    2025-09-19
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 14,342,981effective: 2025-09-19
    Decision targets ZENVARA's direct competitor in NSCLC.
  174. Payerhigh (82%)cms lcdcoverage decision
    2025-09-21
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J15lives: 7,273,679effective: 2025-09-21
    Decision targets ZENVARA's direct competitor in NSCLC.
  175. Payerhigh (81%)cms ncdcoverage decision
    2025-09-22
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,899,922effective: 2025-09-22
    Decision targets ZENVARA's direct competitor in NSCLC.
  176. Payerhigh (80%)pbm medicare pdprestriction added
    2025-09-22
    Humana Pharmacy Solutions added prior-authorization requirement to ZENVARA.
    Humana Pharmacy SolutionsUS-nationallives: 8,430,961effective: 2025-10-31
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA,LA
  177. Payermedium (52%)icervalue assessment final
    2025-09-23
    ICER published final value assessment for ZENVARA in NSCLC.
    ICERUS-nationallives: 79,890,217effective: 2025-09-23
    Decision affects adjacent indication; potential read-through to ZENVARA.
    rating: Dvalue_for_money: intermediateprice_benchmark_usd: 152130
  178. Payerlow (27%)pbm commercialrestriction added
    2025-09-24
    OptumRx added prior-authorization requirement to ZENVARA.
    OptumRxUS-nationallives: 83,989,935effective: 2025-10-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA,PA
  179. Payerlow (30%)pbm commercialtier changed
    2025-09-24
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 99,528,452effective: 2025-10-09
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 5
  180. Payerhigh (86%)pbm medicare pdpadded
    2025-09-24
    CVS Caremark SilverScript added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS Caremark SilverScriptUS-nationallives: 3,284,583effective: 2025-10-18
    Decision targets ZENVARA's direct competitor in NSCLC.
  181. Payerhigh (72%)hospital pt committeeremoved
    2025-09-25
    HCA Healthcare removed ZENVARA from formulary effective 2025-11-22.
    HCA HealthcareUS-nationallives: 1,850,028effective: 2025-11-22
    Decision targets ZENVARA's direct competitor in NSCLC.
  182. Payerhigh (70%)pbm medicare pdpadded
    2025-09-25
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 6,984,777effective: 2025-10-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  183. Payermedium (63%)pbm medicare pdptier changed
    2025-09-26
    OptumRx Medicare moved ZENVARA from preferred to non-preferred tier.
    OptumRx MedicareUS-nationallives: 9,419,390effective: 2025-10-23
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 5
  184. Payermedium (46%)health plan commercialrestriction added
    2025-09-26
    BCBS Federal Employee Program added prior-authorization requirement to ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 15,413,374effective: 2025-11-10
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: LA
  185. Payerlow (31%)pbm medicare pdprestriction added
    2025-09-26
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 11,077,382effective: 2025-10-19
    Decision concerns ZENVARA's reference product.
    restrictions: QL,PA
  186. Payermedium (67%)pbm medicare pdpadded
    2025-10-01
    CVS Caremark SilverScript added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS Caremark SilverScriptUS-nationallives: 7,614,520effective: 2025-10-15
    Decision targets ZENVARA's direct competitor in NSCLC.
  187. Payerlow (21%)pbm commercialexcluded
    2025-10-02
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-10-25.
    OptumRxUS-nationallives: 73,367,527effective: 2025-10-25
    Decision affects adjacent indication; potential read-through to ZENVARA.
  188. Payerhigh (89%)pbm medicare pdprestriction added
    2025-10-02
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 3,879,342effective: 2025-11-18
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,LA
  189. Payermedium (61%)pbm commercialexcluded
    2025-10-02
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-11-23.
    OptumRxUS-nationallives: 91,369,413effective: 2025-11-23
    Decision targets ZENVARA's direct competitor in NSCLC.
  190. Payerlow (29%)state medicaid pdlremoved
    2025-10-03
    Texas HHSC removed ZENVARA from formulary effective 2025-10-22.
    Texas HHSCUS-state:ILlives: 4,558,258effective: 2025-10-22
    Decision concerns ZENVARA's reference product.
  191. Payermedium (50%)health plan commercialrestriction removed
    2025-10-03
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 20,204,776effective: 2025-10-03
    Decision affects adjacent indication; potential read-through to ZENVARA.
  192. Payermedium (49%)state medicaid pdlremoved
    2025-10-03
    Florida AHCA removed ZENVARA from formulary effective 2025-10-20.
    Florida AHCAUS-state:GAlives: 2,789,638effective: 2025-10-20
    Decision concerns ZENVARA's reference product.
  193. Payermedium (66%)pbm commercialexcluded
    2025-10-04
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-11-19.
    OptumRxUS-nationallives: 62,405,297effective: 2025-11-19
    Decision targets ZENVARA's direct competitor in NSCLC.
  194. Payerlow (26%)hta intlvalue assessment final
    2025-10-04
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)EU-FRlives: 22,829,771effective: 2025-10-04
    Decision affects adjacent indication; potential read-through to ZENVARA.
  195. Payerhigh (70%)pbm commercialrestriction added
    2025-10-05
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 69,477,806effective: 2025-11-27
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA
  196. Payerhigh (86%)cms lcdcoverage decision
    2025-10-06
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 5,335,531effective: 2025-10-06
    Decision targets ZENVARA's direct competitor in NSCLC.
  197. Payerlow (25%)pbm commercialstep therapy imposed
    2025-10-06
    OptumRx now requires step therapy through alternative before ZENVARA.
    OptumRxUS-nationallives: 78,695,958effective: 2025-11-26
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: QL
  198. Payermedium (64%)pbm medicare pdptier changed
    2025-10-08
    OptumRx Medicare moved ZENVARA from preferred to non-preferred tier.
    OptumRx MedicareUS-nationallives: 3,568,654effective: 2025-11-29
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 4
  199. Payerhigh (92%)cms lcdcoverage decision
    2025-10-09
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JLlives: 11,298,477effective: 2025-10-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  200. Payerlow (23%)pbm commercialadded
    2025-10-09
    CVS Caremark added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS CaremarkUS-nationallives: 80,386,033effective: 2025-10-23
    Class-wide implications relevant to all assets with this mechanism.
  201. Congresshighembargo lifts in 1d
    Jun 1, 2026, 4:00 PM
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    Median OS 33.8 months. HR 0.8 (95% CI 0.71–0.89). No new safety signals identified.
    Kisqali () · NovartisHR+ breast cancerMONALEESA-38 · NCT60056504Poster Discussion Session
    OS
    33.8 months
    HR 0.8 (0.71-0.89)
    PFS
    22.8 months
    HR 0.77 (0.69-0.86)
    ORR
    77.9 percent
  202. Congresshighembargo lifts in 1d
    Jun 1, 2026, 4:15 PM
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    Median OS 29.4 months. HR 0.85 (95% CI 0.76–0.94). Grade ≥3 AEs consistent with prior reports.
    Enhertu () · Daiichi SankyoNSCLCDESTINY-Breast-376 · NCT30918589Poster Session
    OS
    29.4 months
    HR 0.85 (0.76-0.94)
    PFS
    7.2 months
    HR 0.89 (0.8-0.91)
    ORR
    50.6 percent
  203. Congressmediumembargo lifts in 1d
    Jun 1, 2026, 9:15 PM
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-16
    Median OS 19.6 months. HR 0.75 (95% CI 0.64–0.86). Grade ≥3 AEs consistent with prior reports.
    Tecentriq () · RocheNSCLCIMpower-16 · NCT45181053Trials in Progress Poster Session
    OS
    19.6 months
    HR 0.75 (0.64-0.86)
    PFS
    10.1 months
    HR 0.74 (0.64-0.88)
    ORR
    51.2 percent
  204. Congresslowembargo lifts in 1d
    Jun 1, 2026, 9:45 PM
    KEYNOTE-849: Keytruda (pembrolizumab) 2L in SCLC
    Median OS 10.6 months. HR 0.89 (95% CI 0.77–0.99). No new safety signals identified.
    Keytruda () · MerckSCLCKEYNOTE-849 · NCT63930156Oral Abstract Session
    OS
    10.6 months
    HR 0.89 (0.77-0.99)
    PFS
    4.3 months
    HR 0.87 (0.74-0.99)
    ORR
    61.3 percent
  205. Congressmediumembargo lifts in 1d
    Jun 1, 2026, 10:00 PM
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-560
    Median OS 18 months. HR 0.83 (95% CI 0.71–0.95). No new safety signals identified.
    Keytruda () · MerckTNBCKEYNOTE-560 · NCT60389648Poster Discussion Session
    OS
    18 months
    HR 0.83 (0.71-0.95)
    PFS
    11 months
    HR 0.81 (0.74-0.94)
    ORR
    41.2 percent
  206. Congressmediumembargo lifts in 2d
    Jun 2, 2026, 3:30 PM
    CheckMate-957: Opdivo (nivolumab) neoadjuvant in HCC
    Median OS 19.2 months. HR 0.62 (95% CI 0.51–0.73). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbHCCCheckMate-957 · NCT64844073Education Session
    OS
    19.2 months
    HR 0.62 (0.51-0.73)
    PFS
    8.6 months
    HR 0.64 (0.54-0.74)
    ORR
    32.5 percent
  207. Congresshighembargo lifts in 2d
    Jun 2, 2026, 3:45 PM
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-349
    Median OS 37.6 months. HR 0.68 (95% CI 0.56–0.8). No new safety signals identified.
    Ibrance () · PfizerHR+ breast cancerPALOMA-349 · NCT90598054Oral Abstract Session
    OS
    37.6 months
    HR 0.68 (0.56-0.8)
    PFS
    23.6 months
    HR 0.67 (0.53-0.78)
    ORR
    78 percent
  208. Congresshighembargo lifts in 2d
    Jun 2, 2026, 4:00 PM
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)
    Median OS 28.5 months. HR 0.68 (95% CI 0.55–0.81). Grade ≥3 AEs consistent with prior reports.
    Tagrisso () · AstraZenecaNSCLCFLAURA-312 · NCT74476517Rapid Oral Abstract Session
    OS
    28.5 months
    HR 0.68 (0.55-0.81)
    PFS
    8.8 months
    HR 0.69 (0.54-0.82)
    ORR
    44.2 percent
  209. Congressmediumembargo lifts in 2d
    Jun 2, 2026, 4:45 PM
    Real-world effectiveness of Opdivo vs standard of care in RCC
    Median OS 51.4 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbRCCCheckMate-903 · NCT76925924Oral Abstract Session
    OS
    51.4 months
    HR 0.83 (0.74-0.92)
    PFS
    23.3 months
    HR 0.83 (0.75-0.92)
    ORR
    55.7 percent
  210. Congresshighembargo lifts in 2d
    Jun 2, 2026, 8:30 PM
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    Median OS 35.6 months. HR 0.7 (95% CI 0.62–0.78). Grade ≥3 AEs consistent with prior reports.
    Kisqali () · NovartisHR+ breast cancerMONALEESA-190 · NCT77693036Poster Session
    OS
    35.6 months
    HR 0.7 (0.62-0.78)
    PFS
    20.5 months
    HR 0.74 (0.66-0.81)
    ORR
    55.5 percent
  211. Congressmediumembargo lifts in 2d
    Jun 2, 2026, 9:30 PM
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    Median OS 24 months. HR 0.81 (95% CI 0.69–0.93). No new safety signals identified.
    Keytruda () · MerckTNBCKEYNOTE-968 · NCT24586311Poster Session
    OS
    24 months
    HR 0.81 (0.69-0.93)
    PFS
    7.2 months
    HR 0.79 (0.7-0.97)
    ORR
    40.4 percent
  212. Congressmediumembargo lifts in 3d
    Jun 3, 2026, 3:00 PM
    DESTINY-Breast-179: Enhertu (trastuzumab deruxtecan) adjuvant in gastric
    Median OS 18.8 months. HR 0.88 (95% CI 0.74–0.99). No new safety signals identified.
    Enhertu () · Daiichi SankyogastricDESTINY-Breast-179 · NCT43607208Publication Only
    OS
    18.8 months
    HR 0.88 (0.74-0.99)
    PFS
    7.9 months
    HR 0.89 (0.72-0.97)
    ORR
    49.7 percent
  213. Congresshighembargo lifts in 3d
    Jun 3, 2026, 3:30 PM
    FLAURA-898: Tagrisso (osimertinib) 2L in NSCLC
    Median OS 22.5 months. HR 0.76 (95% CI 0.66–0.86). Grade ≥3 AEs consistent with prior reports.
    Tagrisso () · AstraZenecaNSCLCFLAURA-898 · NCT65454622Poster Session
    OS
    22.5 months
    HR 0.76 (0.66-0.86)
    PFS
    10.5 months
    HR 0.76 (0.68-0.84)
    ORR
    59.6 percent
  214. Congresshighembargo lifts in 3d
    Jun 3, 2026, 3:45 PM
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-410 study)
    Median OS 36.7 months. HR 0.9 (95% CI 0.77–0.99). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-410 · NCT12503018Oral Abstract Session
    OS
    36.7 months
    HR 0.9 (0.77-0.99)
    PFS
    22.3 months
    HR 0.93 (0.8-0.99)
    ORR
    58.8 percent
  215. Congressmediumembargo lifts in 3d
    Jun 3, 2026, 4:45 PM
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-845
    Median OS 29.2 months. HR 0.58 (95% CI 0.48–0.68). Grade ≥3 AEs consistent with prior reports.
    Opdivo () · Bristol-Myers SquibbNSCLCCheckMate-845 · NCT53991773Late-Breaking Oral Abstract Session
    OS
    29.2 months
    HR 0.58 (0.48-0.68)
    PFS
    10.6 months
    HR 0.55 (0.44-0.65)
    ORR
    47.7 percent
  216. Congresshighembargo lifts in 4d
    Jun 4, 2026, 2:00 PM
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-881
    Median OS 29.3 months. HR 0.6 (95% CI 0.51–0.69). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbNSCLCCheckMate-881 · NCT08001951Poster Session
    OS
    29.3 months
    HR 0.6 (0.51-0.69)
    PFS
    7.4 months
    HR 0.61 (0.51-0.72)
    ORR
    60 percent
  217. Congresshighembargo lifts in 4d
    Jun 4, 2026, 4:30 PM
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-190
    Median OS 12.7 months. HR 0.83 (95% CI 0.72–0.94). Grade ≥3 AEs consistent with prior reports.
    Imfinzi () · AstraZenecabiliary tractPACIFIC-190 · NCT97449766Poster Session
    OS
    12.7 months
    HR 0.83 (0.72-0.94)
    PFS
    7.5 months
    HR 0.83 (0.69-0.97)
    ORR
    34.7 percent
  218. Congresshighembargo lifts in 4d
    Jun 4, 2026, 5:00 PM
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-645
    Median OS 22.4 months. HR 0.6 (95% CI 0.5–0.7). Grade ≥3 AEs consistent with prior reports.
    Keytruda () · MerckNSCLCKEYNOTE-645 · NCT22264892Poster Discussion Session
    OS
    22.4 months
    HR 0.6 (0.5-0.7)
    PFS
    7.7 months
    HR 0.64 (0.49-0.67)
    ORR
    45.7 percent
  219. Congresslowembargo lifts in 4d
    Jun 4, 2026, 5:45 PM
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-650
    Median OS 37.5 months. HR 0.87 (95% CI 0.76–0.98). Grade ≥3 AEs consistent with prior reports.
    Lynparza () · AstraZenecaprostateOlympiA-650 · NCT23801137Poster Discussion Session
    OS
    37.5 months
    HR 0.87 (0.76-0.98)
    PFS
    20.3 months
    HR 0.89 (0.75-0.99)
    ORR
    46.8 percent
  220. Congresshighembargo lifts in 4d
    Jun 4, 2026, 7:45 PM
    Quality of life outcomes with Keytruda in patients with NSCLC
    Median OS 25.6 months. HR 0.79 (95% CI 0.7–0.88). Grade ≥3 AEs consistent with prior reports.
    Keytruda () · MerckNSCLCKEYNOTE-433 · NCT65945184Poster Session
    OS
    25.6 months
    HR 0.79 (0.7-0.88)
    PFS
    11.7 months
    HR 0.77 (0.66-0.89)
    ORR
    61.9 percent
  221. Congressmediumembargo lifts in 4d
    Jun 4, 2026, 8:15 PM
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    Median OS 38 months. HR 0.62 (95% CI 0.48–0.76). No new safety signals identified.
    Lynparza () · AstraZenecaHR+ breast cancerOlympiA-594 · NCT43314812Poster Discussion Session
    OS
    38 months
    HR 0.62 (0.48-0.76)
    PFS
    23.1 months
    HR 0.61 (0.47-0.76)
    ORR
    63.1 percent
  222. Congressmediumembargo lifts in 4d
    Jun 4, 2026, 9:00 PM
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-860
    Median OS 20.7 months. HR 0.88 (95% CI 0.76–0.99). No new safety signals identified.
    Tecentriq () · RocheNSCLCIMpower-860 · NCT14419528Education Session
    OS
    20.7 months
    HR 0.88 (0.76-0.99)
    PFS
    11.4 months
    HR 0.85 (0.76-0.96)
    ORR
    40.1 percent
  223. Congressmediumembargo lifts in 4d
    Jun 4, 2026, 9:30 PM
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-252
    Median OS 33.1 months. HR 0.68 (95% CI 0.6–0.76). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-252 · NCT49268597Poster Session
    OS
    33.1 months
    HR 0.68 (0.6-0.76)
    PFS
    21.5 months
    HR 0.65 (0.6-0.78)
    ORR
    74.8 percent
  224. Congresshighembargo lifts in 5d
    Jun 5, 2026, 2:15 PM
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    Median OS 38.2 months. HR 0.9 (95% CI 0.8–0.99). No new safety signals identified.
    Ibrance () · PfizerHR+ breast cancerPALOMA-223 · NCT98838794Oral Abstract Session
    OS
    38.2 months
    HR 0.9 (0.8-0.99)
    PFS
    27.1 months
    HR 0.86 (0.8-0.95)
    ORR
    57.2 percent
  225. Congressmediumembargo lifts in 5d
    Jun 5, 2026, 3:15 PM
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-569 study)
    Median OS 16.4 months. HR 0.85 (95% CI 0.75–0.95). No new safety signals identified.
    Imfinzi () · AstraZenecaNSCLCPACIFIC-569 · NCT82451698Education Session
    OS
    16.4 months
    HR 0.85 (0.75-0.95)
    PFS
    9.1 months
    HR 0.87 (0.78-0.99)
    ORR
    50.7 percent
  226. Congresshighembargo lifts in 5d
    Jun 5, 2026, 5:00 PM
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    Median OS 38.9 months. HR 0.58 (95% CI 0.47–0.69). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-149 · NCT32526973Oral Abstract Session
    OS
    38.9 months
    HR 0.58 (0.47-0.69)
    PFS
    19.4 months
    HR 0.6 (0.48-0.7)
    ORR
    74.7 percent
  227. Congresshighembargo lifts in 5d
    Jun 5, 2026, 5:30 PM
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-419 study)
    Median OS 14.9 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.
    Imfinzi () · AstraZenecaSCLCPACIFIC-419 · NCT88358487Oral Abstract Session
    OS
    14.9 months
    HR 0.83 (0.74-0.92)
    PFS
    6.1 months
    HR 0.81 (0.76-0.89)
    ORR
    63 percent
  228. Congressmediumembargo lifts in 5d
    Jun 5, 2026, 7:15 PM
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-421
    Median OS 12.5 months. HR 0.8 (95% CI 0.72–0.88). Grade ≥3 AEs consistent with prior reports.
    Trodelvy () · Gileadurothelial carcinomaASCENT-421 · NCT53826507Poster Session
    OS
    12.5 months
    HR 0.8 (0.72-0.88)
    PFS
    8.7 months
    HR 0.8 (0.69-0.84)
    ORR
    31.6 percent
  229. Congresshighembargo lifts in 5d
    Jun 5, 2026, 9:30 PM
    MONARCH-789: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    Median OS 37.2 months. HR 0.87 (95% CI 0.75–0.99). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-789 · NCT81284428Rapid Oral Abstract Session
    OS
    37.2 months
    HR 0.87 (0.75-0.99)
    PFS
    24.7 months
    HR 0.85 (0.74-0.99)
    ORR
    58.8 percent
  230. Congresshighembargo lifts in 5d
    Jun 5, 2026, 10:00 PM
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-449
    Median OS 23.5 months. HR 0.86 (95% CI 0.75–0.97). No new safety signals identified.
    Tecentriq () · RocheTNBCIMpower-449 · NCT18767167Poster Session
    OS
    23.5 months
    HR 0.86 (0.75-0.97)
    PFS
    9.9 months
    HR 0.87 (0.73-0.98)
    ORR
    50.8 percent